Stoke Therapeutics to Present at Upcoming Investor Conferences in September

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:

H.C. Wainwright 26th Annual Global Investment Conference

Date: Tuesday, September 10, 2024

Time: 12:00 p.m. ET

2024 Cantor Fitzgerald Global Healthcare Conference

Date: Tuesday, September 17, 2024

Time: 11:30 a.m. ET

Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Contacts

Stoke Investor Contact:
Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com
508-642-6485

0 replies on “Stoke Therapeutics to Present at Upcoming Investor Conferences in September”

Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission

Lukas Podolski’s Kebab Franchise to Roll Out Up To 2,400 Autonomous Food Robots From Circus Group

The Veterinary Cooperative (TVC) Announces Strategic Partnership with Hound to Address Critical Staffing and Burnout Challenges Among Independently Owned Practices

Digital Magazine

Latest Edition – Top 10 Leading Nutanix Partners to Watch in 2024

Latest posts

National Conference on AI Law, Ethics, Safety & Compliance

Telecom industry can accelerate the Fintech Era with Cloud and Generative AI

Shaping the Future of Telecom Networks with Cloud and AI

Artificial Intelligence of Things (AIoT): Leveraging AI in IoT and telecoms

Telecom industry can accelerate the Fintech Era with Cloud and Generative AI

The intersection of cloud computing and generative AI is poised to revolutionize Financial Technology (fintech), ushering in a new era of innovation and efficiency. Fintech, the convergence of finance and

The enterprise tech world is evolving with newer ambitions. While the wings of innovation are spreading to newer skies, the technologists are finding it hard to play catch-up and are making sure they are in tune with the technology juggernaut. CIOCoverage aims to bridge this very gap that exists between the tech-savvy where he rests, in the very heart of it. Awakening a keen insight in you to move along the flow, CIOCoverage works to make the entrepreneurs, versatile to the sturdy technological influences.